SuperworthAclaris Therapeutics shares outstanding ACRS
Diluted shares outstanding, averaged over each quarter, from 2014.
- Latest quarter, to Jun 30, 2026
- 142.7M
- On a year earlier
- +16.4%
- more shares
Aclaris Therapeutics had 142.7M diluted shares outstanding on average in Q2 FY26, the quarter to Jun 30, 2026.
That is 16.4% more than a year earlier, so each share owns a little less of the company.
Shares outstanding over time
Fiscal year by fiscal year
| Fiscal year | Shares, fourth quarter | Change |
|---|---|---|
| FY2025 | 122.7M | +29% |
| FY2024 | 95.3M | +34% |
| FY2023 | 70.9M | +6% |
| FY2022 | 66.7M | +9% |
| FY2021 | 61.2M | +40% |
| FY2020 | 43.6M | +5% |
| FY2019 | 41.4M | +7% |
| FY2018 | 38.8M | +26% |
| FY2017 | 30.8M | +32% |
| FY2016 | 23.4M | +31% |
| FY2015 | 17.8M | +863% |
| FY2014 | 1.9M | n/a |
Each fiscal year is the twelve months to its fourth quarter, shown as the fourth quarter's average share count.
Quarter by quarter
| Quarter | Ended | Shares outstanding | On a year earlier |
|---|---|---|---|
| Q2 FY26 | 142.7M | +16% | |
| Q1 FY26 | 128.8M | +5% | |
| Q4 FY25 | 122.7M | +29% | |
| Q3 FY25 | 122.6M | +72% | |
| Q2 FY25 | 122.6M | +72% | |
| Q1 FY25 | 122.4M | +72% | |
| Q4 FY24 | 95.3M | +34% | |
| Q3 FY24 | 71.4M | +1% | |
| Q2 FY24 | 71.3M | +1% | |
| Q1 FY24 | 71.1M | +6% | |
| Q4 FY23 | 70.9M | +6% | |
| Q3 FY23 | 70.8M | +6% |
What the shares outstanding tells you
Diluted shares outstanding, averaged over the period. Fewer shares means each one owns more of the company.
A falling count usually means buybacks. A rising one means stock pay, acquisitions paid in shares or new shares sold.
More on Aclaris Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.